arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Programma 2023

vrijdag 20 jan

24e Nationale Longkanker Symposium

08:30

Registration

Voorzitter: Dr. Sjaak Burgers, Longarts, NKI-ALV, Amsterdam

09:00

Welcome

Dr. Sjaak Burgers, Longarts, NKI-ALV, Amsterdam en Prof. Paul Baas, Longarts, NKI-ALV, Amsterdam

Biography
Sjaak Burgers is pulmonologist at the Netherlands Cancer Institute in Amsterdam. He has participated in many clinical mesothelioma trials in the past 20 years, both as primary and as subinvestigator.
He was primary investigator of the NVALT 19 study on switch maintenance gemcitabine after the standard first line chemotherapy in mesothelioma and the 2nd line mesothelioma PEMMELA study. He is chair of the mesothelioma working party of the NVALT since 2006 and member of the iMig (international Mesothelioma interest group) board since 2019.
He is also medical advisor for the Dutch patient advocacy group and the IAS, the institution of the Dutch government that executes the financial reimbursements for asbestos victims.

09:05

The Suydersee study: treatment and survival of stage III NSCLC in the Pacific era

Ronald Damhuis, IKNL Research & Development, Amsterdam

Summary presentation
Treatment of stage III NSCLC changed rapidly after the results of the Pacific trial were presented in 2017 at the ESMO meeting in Madrid. After an early access programme and the decision to reimburse consolidation treatment with durvalumab in the Netherlands as of 2019, this regimen was incorporated in the national guideline. Recent subgroup analyses of the Pacific trial, however, suggested that treatment was less effective in Europe, in patients with EGFR or ALK gene alteration, in patients with negative PD-L1, or those with a long delay between the end of radiation and the start of immunotherapy. Aim of the Suydersee study was to evaluate the real-world results of durvalumab in the Netherlands, to review the predictive impact of the various subgroups and to check whether therapy was available in all regions. Also, outcomes will be compared with the results of induction treatment followed by surgery.

Biography
Ronald Damhuis (MD, PhD) works as a clinical epidemiologist at the department of Research&Development at IKNL. His main research interests concern clinical performance indicators, rare thoracic cancers and real-world results of novel treatment options.

 

10-Damhuis-Ronald

09:35

Adjuvant immunotherapy in resectable NSCLC

Dr. Enriqueta Felip, Head, Thoracic Oncology Unit, Vall d’Hebron University Hospital, Barcelona

Biography
Enriqueta Felip is the Head of the Thoracic Cancer Unit within the Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain. Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Dr Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology. She has been Associate Professor at the Autonomous University of Barcelona (UAB) from 2010 to May 2019. She is involved in the training of medical students, residents and particularly in mentoring fellows.
Dr Felip is currently a member of the Spanish Lung Cancer Group (SLCG) and the Spanish Society of Medical Oncology (SEOM). In October 2019, Dr. Felip was elected SEOM Vice-President for the following years 2019-2021.
Dr. Felip is also member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). She was from 2017 to 2021 member of the Board of Directors of IASLC.
Dr Felip has been involved in several initiatives with scientific organizations, among them, as Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. Dr Felip is at present a member of the scientific committee of the SLCG.
Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.
The magnitude of Dr. Felip’s contribution to the biomedical sciences is remarkable as is one of the most cited authors in 2018, 2019, 2020, 2021: Global Highly Cited Researcher (Source: Clarivate Analytics).

 

Summary presentation
t.b.c.

12-Enriqueta-Felip-Font

10:35

Coffee Break

Voorzitter: Dr. Willemijn Theelen - longarts, NKI-AvL, Amsterdam

11:15

The MEDIASTrial: a randomized study

Jelle Bousema, surgeon in training / PhD candidate, Ikazia hospital / Maxima MC, Eindhoven

Biograpy
Surgeon in training in the Ikazia hospital / Erasmus MC.
PhD candidate at the Maxima MC / University of Amsterdam.

Summary
Resectable non-small cell lung cancer (NSCLC) with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography and, in case of negative results, confirmatory mediastinoscopy according to current guidelines. However, the added value of mediastinoscopy is under debate. Randomized data regarding immediate lung tumor resection following systematic endosonography versus additional confirmatory mediastinoscopy before resection are lacking.

We randomly assigned patients with (suspected) resectable NSCLC and an indication for mediastinal staging after negative systematic endosonography to immediate lung tumor resection or confirmatory mediastinoscopy followed by tumor resection. The primary outcome in this non-inferiority trial was the presence of unforeseen N2 disease following tumor resection with lymph node dissection. Based on this non-inferiority margin in the rate of unforeseen N2, confirmatory mediastinoscopy after negative systematic endosonography can be omitted in patients with resectable NSCLC and an indication for mediastinal staging.

 

Jelle

11:45

Staging of the Mediastinum

Prof. Eric Lim, The Royal Brompton Hospital, London, United Kingdom

Biography
Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London.
Professor Lim is a sub-specialist in Thoracic Surgery with specific expertise in lung and other chest cancers. His technical expertise is minimally invasive (keyhole) surgery for lung cancer, pleural effusion, pneumothorax and other chest cancers, as well as complex surgery for advanced lung cancer involving airway and blood vessel reconstruction (to save as much normal lung as possible).
He is the national chair for thoracic academia with an active interest in clinical trials serving as Chief Investigator for UK wide National Institute of Healthcare Research funded multicentre trials of surgery for mesothelioma (MARS 2), VATS lobectomy (VIOLET) and local consolidative treatment for advanced lung cancer (RAMON).

Summary presentation
Clinicians often like to think forwards when considering options for staging the mediastium, but often do not consider “why” it should be done, the aims, the costs (time, expense and complications). The best clinical decisions are usually made by first defining the “why” and then working backward to find out how best to acheive it. In the talk, I will revisit the question from ground level up, first defining why we stage the mediastinum, why and when (at all) if we should consider invasive options and where the field is currently moving in 2023 and beyond.

9-Lim-Eric

12:15

How to implement small molecules during RT schedules

Dr. José Belderbos, Radiotherapeut, NKI-AVL, Amsterdam

12:45

Meester van de Medicijnen

Paul Lebbink, Transvaal Apotheek, Den Haag

Biography:
Openbaar apotheker Transvaal Apotheek Den Haag  (1988 – nu).
Lid Centraal Tucht College Gezondheidszorg.
Lid Palliatieve Helpdesk Den Haag en omstreken
Erevoorzitter werkgroep Praktische Farmacie KNMP
Getrouwd met Sonja Keizers,  2 kinderen, Julia en Felix

Abstract:
De taak van de apotheker is om medicatie (al dan niet op recept) te verstrekken aan patiënten, en de patiënten te begeleiden bij het gebruik ervan. Niet alle gewenste medicatie is beschikbaar. De apotheker kan zo nodig medicatie zelf bereiden.

In voorbije tijden maakte de apotheker alle medicatie zelf. Door de opkomst van de industrie is dat niet meer nodig. Welke medicatie kan de apotheker bereiden? Wat is de (toegevoegde) waarde van de eigen bereiding door apothekers? Welke kwaliteit heeft de apotheekbereiding? Is de door apothekers zelf geproduceerde medicatie veilig?

 

13:15

Lunch break

Voorzitter: Prof. Paul Baas, Longarts, NKI-ALV, Amsterdam

14:15

Treatment of MPM in 2023

Prof. Rolf Stahel, ETOP IBCSG Partners Foundation, Bern

Biography
Rolf A. Stahel, M.D. is president of the ETOP IBCSG Partners Foundation. He is editor-in-chief of Lung Cancer and editor of Cancer Treatment Reviews. He was chair of the Comprehensive Cancer Center Zürich, co-chair of the Center for Lung and Thoracic Oncology until 2020. He was ESMO president 2014 and 2015 and currently serves a member of the ESMO council. His major research interests are clinical and translational studies in thoracic oncology.

Summary presentation
The WHO 2021 classification of pleural tumors has added granularity to the diagnosis of malignant pleural mesothelioma and defined mesothelioma in situ as a clinico-pathologic entity through the demonstration of loss of BAP1 or MTAP by immunohistochemistry, or CDKN2A homozygous deletion by FISH. The role of surgery for malignant pleural mesothelioma remains controversial and might become better defined by the results of the MARS2 trial. Regarding first line systemic therapy combined ipilimumab and nivolumab has become a new standard of care, in particular for non-epitheloid subtypes. For epithelial subtypes platin pemetrexed combinations with or without bevacizumab remain an alternative. Readouts of randomized phase III trials on the role of immune checkpoint inhibition added to chemotherapy and of maintenance therapy with dendritic cell loaded with tumor lysates are expected during the year 2023. In second line, the addition of ramucirumab to gemcitabine provides a survival advantage. Biomarker targeted approaches in later line have been explored for tumors with ASS1-loss, BAP1-loss, CDKN2A mutation and mesothelin overexpression with no or limited success. For N2 and LATS deficient mesothelioma targeting the YAP/TEAD interaction with TEAD inhibitors is currently being explored. Based on phase II results with lurbinectedin a phase III trial is under consideration.

17-Stahel-Rolf

14:45

The PEMMELA study, new second line treatment in mesothelioma?

Dr. Sjaak Burgers, Longarts, NKI-ALV, Amsterdam

Biography
Sjaak Burgers is pulmonologist at the Netherlands Cancer Institute in Amsterdam. He has participated in many clinical mesothelioma trials in the past 20 years, both as primary and as subinvestigator.
He was primary investigator of the NVALT 19 study on switch maintenance gemcitabine after the standard first line chemotherapy in mesothelioma and the 2nd line mesothelioma PEMMELA study. He is chair of the mesothelioma working party of the NVALT since 2006 and member of the iMig (international Mesothelioma interest group) board since 2019.
He is also medical advisor for the Dutch patient advocacy group and the IAS, the institution of the Dutch government that executes the financial reimbursements for asbestos victims.

Summary
The therapeutic options for mesothelioma are slowly expanding. First line immunotherapy has entered the therapeutic arena next to chemotherapy in the epithelial mesothelioma subtype, and as superior treatment for the non-epithelial subtypes. Treatments with a proven benefit in second line are urgently needed.

The PEMMELA trial is a non-randomized phase II study for mesothelioma patients who are treated in 2nd or 3rd line. The study treatment consists of the PD-1 blocking antibody pembrolizumab and the multikinase lenvatinib. Lenvatinib targets, amongst others, vascular endothelial growth factor (VEGF) receptors 1 to 3, fibroblast growth factor (FGF) receptors 1 to 4, platelet-derived growth factor receptor-α (PDGRα) and the oncogenes RET and KIT. The combination pembrolizumab – lenvatinib has proven its efficacy in other tumor types. We will describe its effect in mesothelioma.

 

15:15

T cell therapy in NSCLC

Dr. Willemijn Theelen - longarts, NKI-AvL, Amsterdam

15:45

Phase 1 trials: the end or the beginning?

Dr. Gerrina Ruiter, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam

Biography
Dr. Gerrina Ruiter is a pulmonologist specialized in Thoracic Oncology. She is part of the Phase 1 clinical and research team of the Netherlands Cancer Institute.

Summary
A brief overview of the development of phase 1 trials in the Thoracic Oncology field. Several items will be adressed such as: which patients should we select for these trials? What kind of drugs are tested? Is it really worth the effort for both the patient and the treating or referring physician?

gerrina

16:15

Reception